GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (MIL:1BMRN) » Definitions » Investments And Advances

Biomarin Pharmaceutical (MIL:1BMRN) Investments And Advances : €571 Mil (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Biomarin Pharmaceutical Investments And Advances?

Biomarin Pharmaceutical's Investments And Advances for the quarter that ended in Mar. 2024 was €571 Mil.

Biomarin Pharmaceutical's quarterly Investments And Advances increased from Sep. 2023 (€513 Mil) to Dec. 2023 (€560 Mil) and increased from Dec. 2023 (€560 Mil) to Mar. 2024 (€571 Mil).

Biomarin Pharmaceutical's annual Investments And Advances declined from Dec. 2021 (€449 Mil) to Dec. 2022 (€315 Mil) but then increased from Dec. 2022 (€315 Mil) to Dec. 2023 (€560 Mil).


Biomarin Pharmaceutical Investments And Advances Historical Data

The historical data trend for Biomarin Pharmaceutical's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Investments And Advances Chart

Biomarin Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Investments And Advances
Get a 7-Day Free Trial Premium Member Only Premium Member Only 370.78 234.66 449.40 315.14 560.41

Biomarin Pharmaceutical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Investments And Advances Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 318.15 356.07 513.48 560.41 570.91

Biomarin Pharmaceutical Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.


Biomarin Pharmaceutical (MIL:1BMRN) Business Description

Traded in Other Exchanges
Address
770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the U.S. in 2023.

Biomarin Pharmaceutical (MIL:1BMRN) Headlines

No Headlines